alln-177

Small moleculeexperimental

Clinical trial activity

5 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
5
Phase 3
1
Phase 4
0

Earliest trial started Sep 1, 2014 (NCT02289755)

Timeline

2010s

  1. Jan 1, 2014

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2018

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • OXDCSupplementation

    OXDC supplementation

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • alln-177

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03391804Phase 2Jul 17, 2018Allena Pharmaceuticals
NCT03456830Phase 3May 21, 2018Allena Pharmaceuticals
NCT02547805Phase 2Sep 1, 2015Allena Pharmaceuticals
NCT02503345Phase 2Jul 1, 2015Allena Pharmaceuticals
NCT02289755Phase 2Sep 1, 2014Allena Pharmaceuticals
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Allena PharmaceuticalsFor profit5522014
1 organizations
Page 1 / 1